This model deletes the Imprinting Control Region upstream of the H19 promoter and recapitulates the molecular phenotype of BWS patients: biallelic (i.e. 2× dosage) IGF2 and reduced H19 RNA. This evidence concerns the gene IGF2 and Beckwith-Wiedemann syndrome.